Causeway Capital Management LLC Decreases Stock Holdings in Pfizer Inc. (NYSE:PFE)

Causeway Capital Management LLC trimmed its stake in shares of Pfizer Inc. (NYSE:PFE) by 17.1% during the 4th quarter, HoldingsChannel.com reports. The firm owned 1,832,790 shares of the biopharmaceutical company’s stock after selling 378,520 shares during the quarter. Pfizer makes up 1.1% of Causeway Capital Management LLC’s investment portfolio, making the stock its 26th largest position. Causeway Capital Management LLC’s holdings in Pfizer were worth $48,624,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of PFE. XTX Topco Ltd lifted its holdings in Pfizer by 69.9% in the 4th quarter. XTX Topco Ltd now owns 61,341 shares of the biopharmaceutical company’s stock valued at $1,627,000 after purchasing an additional 25,231 shares in the last quarter. Broyhill Asset Management acquired a new stake in Pfizer in the 4th quarter valued at about $231,000. Belpointe Asset Management LLC grew its holdings in Pfizer by 2.4% in the 4th quarter. Belpointe Asset Management LLC now owns 231,398 shares of the biopharmaceutical company’s stock valued at $6,713,000 after buying an additional 5,333 shares in the last quarter. CreativeOne Wealth LLC increased its holdings in shares of Pfizer by 15.2% during the 4th quarter. CreativeOne Wealth LLC now owns 135,564 shares of the biopharmaceutical company’s stock worth $3,597,000 after buying an additional 17,891 shares during the last quarter. Finally, Mariner LLC lifted its holdings in Pfizer by 12.5% in the fourth quarter. Mariner LLC now owns 1,528,785 shares of the biopharmaceutical company’s stock valued at $40,558,000 after acquiring an additional 169,712 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Stock Up 1.4 %

Pfizer stock opened at $21.89 on Monday. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $31.54. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The stock’s 50 day moving average price is $25.25 and its 200 day moving average price is $26.38. The company has a market cap of $124.14 billion, a PE ratio of 15.52, a price-to-earnings-growth ratio of 0.64 and a beta of 0.67.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, topping the consensus estimate of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. During the same period in the prior year, the business posted $0.10 earnings per share. The firm’s revenue for the quarter was up 24.7% compared to the same quarter last year. On average, sell-side analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have commented on PFE shares. Citigroup reaffirmed a “neutral” rating on shares of Pfizer in a research report on Thursday, March 27th. The Goldman Sachs Group reiterated a “neutral” rating and issued a $25.00 target price (down previously from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. Truist Financial cut their price objective on Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a report on Wednesday, December 18th. UBS Group decreased their price target on shares of Pfizer from $28.00 to $24.00 and set a “neutral” rating for the company in a research report on Tuesday, April 8th. Finally, Guggenheim reissued a “buy” rating on shares of Pfizer in a research note on Tuesday, March 18th. One analyst has rated the stock with a sell rating, eight have issued a hold rating, six have given a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat.com, Pfizer presently has a consensus rating of “Moderate Buy” and an average price target of $31.07.

Insider Transactions at Pfizer

In other Pfizer news, Director Ronald E. Blaylock purchased 19,457 shares of the stock in a transaction dated Thursday, February 13th. The shares were acquired at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the transaction, the director now directly owns 27,707 shares of the company’s stock, valued at $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Corporate insiders own 0.06% of the company’s stock.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.